ChiCTR2100049104

Untitled Trial

A Global, Multi center, Randomized, Double Blind, Placebo controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of Novel Coronavirus (mRNA) Vaccine in Population Aged 18 Years and Older
Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region·Phase 3·Chinese Clinical Trial RegistryNot yet recruiting
View on Chinese Clinical Trial Registry
Study focus
Sponsor & location
Primary sponsor
Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region
Funder
Self financed
Location
China
Timeline & enrollment
Phase
Phase 3
Start date
N/A
End date
Mar 31, 2023
ICD-10 classifications
COVID-19, virus identifiedViral pneumonia, unspecifiedOther viral pneumoniaCOVID-19, virus not identifiedPneumonia in viral diseases classified elsewhere
Data source
Registry
Chinese Clinical Trial Registry
Trial ID
ChiCTR2100049104
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for ChiCTR2100049104 through Pure Global AI's free database. This Phase 3 trial is sponsored by Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region and is currently Not yet recruiting. The study focuses on Novel Coronavirus Pneumonia (COVID 19).

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.